05.01.08
New research accepted for publication in the Journal of Psychopharmacology demonstrates that Pycnogenol may improve the memory of senior citizens.
Study results revealed Pycnogenol improved both numerical working memory as well as spatial working memory using a computerized testing system. Dr. Con Stough led the double-blind, placebo-controlled, matched pairs study, which was held at the Centre for Neuropsychology at Swinburne University, Melbourne, Australia. The study examined the effects of Pycnogenol on a range of cognitive and biochemical measures in 101 seniors aged 60 to 85 years old. The study also examined the “oxidative stress” hypothesis of aging and neurological degeneration as it relates to normal changes in cognition in elderly individuals. Participants consumed a daily dose of 150 mg of Pycnogenol for a 3-month treatment period and were assessed at baseline then at 1, 2 and 3 months into treatment. The control and Pycnogenol groups were matched by age, gender, BMI (body mass index), micronutrient intake and intelligence. The cognitive tasks comprised measures of attention, working memory, episodic memory and psycho-motor performance.
After 3 months of treatment, a marker known as F2-isoprostanes significantly decreased with Pycnogenol, but not in the placebo group. F2-isoprostanes develop through the oxidation of unsaturated fatty acids, which are present in particularly high quantities in nerve cell membranes. Results suggest that the antioxidant activity of Pycnogenol plays a major role in producing these clinical effects.
For further information: 312-546-3508.
Study results revealed Pycnogenol improved both numerical working memory as well as spatial working memory using a computerized testing system. Dr. Con Stough led the double-blind, placebo-controlled, matched pairs study, which was held at the Centre for Neuropsychology at Swinburne University, Melbourne, Australia. The study examined the effects of Pycnogenol on a range of cognitive and biochemical measures in 101 seniors aged 60 to 85 years old. The study also examined the “oxidative stress” hypothesis of aging and neurological degeneration as it relates to normal changes in cognition in elderly individuals. Participants consumed a daily dose of 150 mg of Pycnogenol for a 3-month treatment period and were assessed at baseline then at 1, 2 and 3 months into treatment. The control and Pycnogenol groups were matched by age, gender, BMI (body mass index), micronutrient intake and intelligence. The cognitive tasks comprised measures of attention, working memory, episodic memory and psycho-motor performance.
After 3 months of treatment, a marker known as F2-isoprostanes significantly decreased with Pycnogenol, but not in the placebo group. F2-isoprostanes develop through the oxidation of unsaturated fatty acids, which are present in particularly high quantities in nerve cell membranes. Results suggest that the antioxidant activity of Pycnogenol plays a major role in producing these clinical effects.
For further information: 312-546-3508.